Eli Lilly Target Rises to $1,350 After 73.6% Foundayo Weight Loss, $1B Alzheimer’s Deal
LLY•Jefferies raised its price target on Eli Lilly to $1,350, implying 18.1% upside after Foundayo delivered 73.6% weight loss and retatrutide up to 28.3%. Shares hit $1,149.15, lifting market cap to $1.07 trillion, and the company licensed Alzheimer’s candidate ACD680 in a deal worth over $1 billion, including $10 million upfront.
1. Analyst Upgrade and Price Target Increase
Jefferies raised its price target on Eli Lilly shares to $1,350 from $1,330, implying an 18.1% upside based on midday stock trading at $1,143.35 on June 9, 2026. The upgrade reflects growing optimism around the company’s pipeline momentum.
2. Strong Diabetes and Obesity Trial Results
In a head-to-head analysis, Eli Lilly’s oral diabetes drug Foundayo achieved superior long-term blood sugar control and delivered 73.6% greater relative weight loss than a competing oral treatment. Meanwhile, data on investigational candidate retatrutide showed up to 28.3% body weight reduction in trial participants.
3. Record Share Price and Market Capitalization
Investor enthusiasm propelled Eli Lilly shares to an all-time high of $1,149.15, a roughly 4% intraday gain, lifting the company’s market capitalization to approximately $1.07 trillion. The rally underscores confidence in both late-stage and early-stage assets.
4. Billion-Dollar Alzheimer’s Licensing Agreement
Eli Lilly secured global rights to AlzeCure’s preclinical Alzheimer’s candidate ACD680 in a licensing deal valued at over $1 billion, which includes a $10 million upfront payment, milestone fees and tiered royalties. The agreement marks a strategic expansion into neuroscience despite the space’s high clinical risk.
